Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 121

Similar articles for PubMed (Select 22888973)

1.

Comparison of 18F-fluorodeoxyglucose uptake with the expressions of glucose transporter type 1 and Na+/I- symporter in patients with untreated papillary thyroid carcinoma.

Moon SH, Oh YL, Choi JY, Baek CH, Son YI, Jeong HS, Choe YS, Lee KH, Kim BT.

Endocr Res. 2013;38(2):77-84. doi: 10.3109/07435800.2012.713426. Epub 2012 Aug 13.

PMID:
22888973
2.

Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma.

Min JJ, Chung JK, Lee YJ, Jeong JM, Lee DS, Jang JJ, Lee MC, Cho BY.

Eur J Nucl Med. 2001 May;28(5):639-45.

PMID:
11383871
3.

Non-FDG-avid primary papillary thyroid carcinoma may not differ from FDG-avid papillary thyroid carcinoma.

Kim MH, Ko SH, Bae JS, Lee SH, Jung CK, Lim DJ, Baek KH, Kim SH, Lee JM, Kang MI, Cha BY.

Thyroid. 2013 Nov;23(11):1452-60. doi: 10.1089/thy.2013.0051. Epub 2013 Sep 19.

PMID:
23688271
4.
5.

Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma.

Grabellus F, Nagarajah J, Bockisch A, Schmid KW, Sheu SY.

Clin Nucl Med. 2012 Feb;37(2):121-7. doi: 10.1097/RLU.0b013e3182393599.

PMID:
22228332
6.

Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.

Chung JK, So Y, Lee JS, Choi CW, Lim SM, Lee DS, Hong SW, Youn YK, Lee MC, Cho BY.

J Nucl Med. 1999 Jun;40(6):986-92.

7.

Clinical value of visually identifiable 18F-fluorodeoxyglucose uptake in primary papillary thyroid microcarcinoma.

Hwang SO, Lee SW, Kang JK, Choi HH, Kim WW, Park HY, Jung JH.

Otolaryngol Head Neck Surg. 2014 Sep;151(3):415-20. doi: 10.1177/0194599814537224. Epub 2014 Jun 5.

PMID:
24903453
8.

Factors associated with positive F-18 flurodeoxyglucose positron emission tomography before thyroidectomy in patients with papillary thyroid carcinoma.

Kim BS, Kim SJ, Kim IJ, Pak K, Kim K.

Thyroid. 2012 Jul;22(7):725-9. doi: 10.1089/thy.2011.0031. Epub 2012 Apr 23.

9.

Visually discernible [18F]fluorodeoxyglucose uptake in papillary thyroid microcarcinoma: a potential new risk factor.

Yun M, Noh TW, Cho A, Choi YJ, Hong SW, Park CS, Lee JD, Kim CK.

J Clin Endocrinol Metab. 2010 Jul;95(7):3182-8. doi: 10.1210/jc.2009-2091. Epub 2010 Apr 28.

PMID:
20427505
10.

Clinicopathologic characteristics of synchronous primary thyroid cancer detected by initial staging 18F-FDG PET-CT examination in patients with underlying malignancy.

Kim BH, Lee CH, Kim SJ, Jeon YK, Kim SS, Kim YK, Kim IJ.

Thyroid. 2013 Nov;23(11):1431-6. doi: 10.1089/thy.2012.0546. Epub 2013 Jul 25.

11.

Sodium-iodide symporter (NIS) gene expression in lymph-node metastases of papillary thyroid carcinomas.

Arturi F, Russo D, Giuffrida D, Schlumberger M, Filetti S.

Eur J Endocrinol. 2000 Nov;143(5):623-7.

12.

Characteristics of primary papillary thyroid carcinoma with false-negative findings on initial (18)F-FDG PET/CT.

Choi JW, Yoon YH, Yoon YH, Kim SM, Koo BS.

Ann Surg Oncol. 2011 May;18(5):1306-11. doi: 10.1245/s10434-010-1469-2. Epub 2010 Dec 8.

PMID:
21140231
13.

Correlations between SUVmax and expression of GLUT1 and growth factors inducing lymphangiogenesis.

Tian M, Yu L, Zhang Y, Gao X.

Acad Radiol. 2012 Apr;19(4):420-6. doi: 10.1016/j.acra.2011.12.006.

PMID:
22444673
14.
15.

The clinical impact of 18F-FDG PET in papillary thyroid carcinoma with a negative 131I whole body scan: a single-center study of 108 patients.

Choi MY, Chung JK, Lee HY, So Y, Park do J, Jeong JM, Lee DS, Lee MC, Cho BY.

Ann Nucl Med. 2006 Oct;20(8):547-52.

PMID:
17134022
16.

Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma.

Shiga T, Tsukamoto E, Nakada K, Morita K, Kato T, Mabuchi M, Yoshinaga K, Katoh C, Kuge Y, Tamaki N.

J Nucl Med. 2001 Mar;42(3):414-9.

17.
18.

Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels.

Muros MA, Llamas-Elvira JM, Ramírez-Navarro A, Gómez MJ, Rodríguez-Fernández A, Muros T, López de la Torre M, Becerra A, Carreras JL.

Am J Surg. 2000 Jun;179(6):457-61.

PMID:
11004330
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk